Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.
Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience.
复制标题
DOI：
10.3892/ol.2013.1408
复制
发表时间：
2013-08
期刊：
影响因子：
2.9
通讯作者：
Buyukberber S
中科院分区：
文献类型：
--
作者：
Kefeli U;Benekli M;Sevinc A;Yildiz R;Kaplan MA;Ciltas A;Balakan O;Isikdogan A;Coskun U;Dane F;Harputluoglu H;Karaca H;Yazilitas D;Durnali A;Kaya AO;Demirci U;Gumus M;Buyukberber S
索拉非尼是一种多靶点酪氨酸激酶受体抑制剂，用于治疗晚期胃肠道间质瘤（GIST）患者。本研究评价索拉非尼治疗GIST患者的疗效和耐受性。在2001年1月至2012年11月期间，对来自多个中心的25例接受索拉非尼作为GIST三线或四线治疗的患者进行了回顾性研究。共有17名患者为男性，8名为女性。中位年龄为54.0岁（范围：16-82岁）。在这些患者中，21人接受伊马替尼治疗超过6个月，4人接受不到6个月。索拉非尼的临床获益率为40.0%。72%的患者报告了治疗相关不良事件。这些不良事件的严重程度通常为轻度至中度。接受索拉非尼治疗的患者的中位无进展生存期（PFS）和总生存期（OS）时间分别为7.2和15.2个月。伊马替尼使用的持续时间是PFS和OS的独立预后因素。索拉非尼是GIST患者的有效治疗，临床获益率为40.0%，耐受性可接受。
Sorafenib is a multi-targeted tyrosine kinase receptor inhibitor used to treat patients with advanced gastrointestinal stromal tumors (GISTs). The present study evaluated the efficacy and tolerability of sorafenib therapy for patients with GISTs. Between January 2001 and November 2012, 25 patients, from multiple centers, who had received sorafenib as the third- or fourth-line treatment for GISTs were investigated retrospectively. In total, 17 patients were male and eight were female. The median age was 54.0 years (range, 16–82 years). From the patients, 21 received imatinib for longer than six months and four received it for less than six months. The clinical benefit rate of sorafenib was 40.0%. Treatment-related adverse events were reported in 72% of patients. These adverse events were generally mild to moderate in intensity. The median progression-free survival (PFS) and overall survival (OS) times of the patients who received sorafenib were 7.2 and 15.2 months, respectively. The duration of imatinib usage was an independent prognostic factor for PFS and OS. Sorafenib is an effective treatment in patients with GISTs showing a clinical benefit rate of 40.0% and an acceptable tolerability.
登录
查看更多内容
影响因子：
8.4
作者：
Eisenhauer, E. A.;Therasse, P.;Verweij, J.
通讯作者：
Verweij, J.
影响因子：
4.3
作者：
Chen, Yen-Yang;Yeh, Chun-Nan;Chen, Miin-Fu
通讯作者：
Chen, Miin-Fu
影响因子：
9.8
作者：
Osusky, Katherine L.;Hallahan, Dennis E.;Geng, Luis
通讯作者：
Geng, Luis
影响因子：
45.3
作者：
Heinrich, MC;Corless, CL;Fletcher, JA
通讯作者：
Fletcher, JA
影响因子：
9
作者：
NG, EH;POLLOCK, RE;ROMSDAHL, MM
通讯作者：
ROMSDAHL, MM